Brief: Ultimovacs Updates On Timeline For Readout Of Initium Study Of UV1 In Malignant Melanoma

Zelluna ASA

25/04/2023 06:23

April 25 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * ULTIMOVACS PROVIDES UPDATED GUIDANCE ON TIMELINE FOR
READOUT OF
INITIUM PHASE II CLINICAL TRIAL OF UV1 IN MALIGNANT MELANOMA
    * IT IS TAKING LONGER THAN ESTIMATED FOR PATIENTS IN INITIUM
STUDY
TO EXPERIENCE DISEASE PROGRESSION, WHICH IS POSITIVE FOR
PATIENTS
    * RESULTS WILL BE DISCLOSED AFTER CANCER PROGRESSION HAS
BEEN
VERIFIED IN 70 PATIENTS, WHICH HAS NOT YET OCCURRED
    * GUIDANCE FOR READOUT IS CONSEQUENTLY ADJUSTED FROM FIRST
HALF TO
SECOND HALF OF 2023
    * ADJUSTED GUIDANCE FROM FIRST HALF OF 2023 TO SECOND HALF
OF 2023
FOR COMMUNICATION OF TOPLINE PFS DATA FROM INITIUM PHASE II
TRIAL

Source text for Eikon:  ID:nGNE41zHM 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))